Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD Indicated in adults for the treatment of patients of Chronic Kidney Disease up to eGFR greater than or equal to 25 ml per min per 1.73 m2 AstraZeneca